Low-Dosage inhibition of DLL4 signaling promotes wound healing by inducing functional Neo-Angiogenesis

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Trindade, Alexandre ^a,b   Djokovic, Dusan ^a,b   Gigante, Joana ^a   Badenes, Marina ^a   Pedrosa, Ana Rita ^a   Fernandes, Ana Carina ^a   Lopes da Costa, Luís ^a   Krasnoperov, Valery ^c   Liu, Ren ^d   Gill, Parkash S ^d,e   Duarte, António ^a,b  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^c Vasgene Therapeutics   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA LIKE LIGAND 4; IMMUNOGLOBULIN FC FRAGMENT; NOTCH RECEPTOR; PROTEIN INHIBITOR; SOLUBLE DELTA LIKE LIGAND 4 EXTRACELLULAR DOMAIN IMMUNOGLOBULIN FC FRAGMENT; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; DLL4 FC PROTEIN; DLL4 PROTEIN, MOUSE; DLL4-FC PROTEIN; HEY2 PROTEIN, MOUSE; HYBRID PROTEIN; MEMBRANE PROTEIN; REPRESSOR PROTEIN; SIGNAL PEPTIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL FUNCTION; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME INHIBITION; HYPOXEMIA; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TISSUE GROWTH; TISSUE PERFUSION; VASCULARIZATION; WOUND HEALING; ANIMAL; BLOOD VESSEL; C57BL MOUSE; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; REGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN;

MUS;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BLOOD VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECOMBINANT FUSION PROTEINS; REGENERATION; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; WOUND HEALING;

EID: 84855938803     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029863     Document Type: Article

References (42)

1. Karamysheva AF, (2008) Mechanisms of angiogenesis. Biochemistry (Mosc) 73: 751-762.
2. Eming SA, Brachvogel B, Odorisio T, Koch M, (2007) Regulation of angiogenesis: wound healing as a model. Prog Histochem Cytochem 42: 115-170.
3. Li J, Zhang YP, Kirsner RS, (2003) Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech 60: 107-114.
4. Gurtner GC, Werner S, Barrandon Y, Longaker MT, (2008) Wound repair and regeneration. Nature 453: 314-321.
5. Madeddu P, (2005) Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol 90: 315-326.
6. Tongers J, Roncalli JG, Losordo DW, (2008) Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. Circulation 118: 9-16.
7. Franz MG, Steed DL, Robson MC, (2007) Optimizing healing of the acute wound by minimizing complications. Curr Probl Surg 44: 691-763.
8. Balfour JAB, Noble S, (1999) Becaplermin. BioDrugs 11: 359-364.
9. Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, et al. (2000) Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev 14: 1313-1318.
10. Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, et al. (2004) Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev 18: 2474-2478.
11. Benedito R, Duarte A, (2005) Expression of Dll4 during mouse embryogenesis suggests multiple developmental roles. Gene Expr Patterns 5: 750-755.
12. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, et al. (2007) Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 109: 4753-4760.
13. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, et al. (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444: 1032-1037.
14. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, et al. (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444: 1083-1087.
15. Chigurupati S, Arumugam TV, Son TG, Lathia JD, Jameel S, et al. (2007) Involvement of notch signaling in wound healing. PLoS ONE 2: e1167.
16. Trindade A, Ram Kumar S, Scehnet JS, Lopes-da-Costa L, Becker J, et al. (2008) Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood 112: 1720-1729.
17. Williams CK, Li JL, Murga M, Harris AL, Tosato G, (2006) Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107: 931-939.
18. Thurston G, Noguera-Troise I, Yancopoulos GD, (2007) The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 7: 327-331.
19. Koch U, Fiorini E, Benedito R, Besseyrias V, Schuster-Gossler K, et al. (2008) Delta-like 4 is the essential, nonredundant ligand for Notch1 during thymic T cell lineage commitment. J Exp Med 205: 2515-2523.
20. Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, et al. (2003) Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell 4: 31-39.
21. Djokovic D, Trindade A, Gigante J, Badenes M, Silva L, et al. (2010) Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer 10: 641.
22. Fung E, Tang SM, Canner JP, Morishige K, Arboleda-Velasquez JF, et al. (2007) Delta-like 4 induces notch signaling in macrophages: implications for inflammation. Circulation 115: 2948-2956.
23. Segarra M, Williams CK, Sierra Mde L, Bernardo M, McCormick PJ, et al. (2008) Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood 112: 1904-1911.
24. Williams CK, Li J-L, Murga M, Harris AL, Tosato G, (2006) Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107: 931-939.
25. Borggrefe T, Oswald F, (2009) The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci 66: 1631-1646.
26. Mosch B, Reissenweber B, Neuber C, Pietzsch J, (2010) Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. Journal of Oncology 2010: 135285.
27. Erber R, Eichelsbacher U, Powajbo V, Korn T, Djonov V, et al. (2006) EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J 25: 628-641.
28. Jakobsson L, Bentley K, Gerhardt H, (2009) VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans 37: 1233-1236.
29. Hogan BM, Herpers R, Witte M, Heloterä H, Alitalo K, et al. (2009) Vegfc/Flt4 signalling is suppressed by Dll4 in developing zebrafish intersegmental arteries. Development 136: 4001-4009.
30. Shibuya M, (2008) Vascular endothelial growth factor-dependent and-independent regulation of angiogenesis. BMB Rep 41: 278-286.
31. Thomas M, Augustin HG, (2009) The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 12: 125-137.
32. Butler MG, Isogai S, Weinstein BM, (2009) Lymphatic development. Birth Defects Res C Embryo Today 87: 222-231.
33. Niessen K, Zhang G, Ridgway JB, Chen H, Kolumam G, et al. (2011) The Notch1-Dll4 signaling pathway regulates mouse postnatal lymphatic development. Blood 118: 1989-1997.
34. Phng L-K, Gerhardt H, (2009) Angiogenesis: a team effort coordinated by notch. Dev Cell 16: 196-208.
35. Yan M, Plowman GD, (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res 13: 7243-7246.
36. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, et al. (2010) Chronic DLL4 blockade induces vascular neoplasms. Nature 463: E6-7.
37. Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, et al. (2008) Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454: 656-660.
38. Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, et al. (1999) Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes & Development 13: 295-306.
39. Foo SS, Turner CJ, Adams S, Compagni A, Aubyn D, et al. (2006) Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell 124: 161-173.
40. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, et al. (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature.
41. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, et al. (2010) Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature.
42. Armulik A, Abramsson A, Betsholtz C, (2005) Endothelial/pericyte interactions. Circ Res 97: 512-523.